Literature DB >> 16329530

Viral infections in the elderly. The challenges of managing herpes zoster, influenza, and RSV.

Mazen S Bader1, David S McKinsey.   

Abstract

Viral diseases are an important cause of morbidity and mortality in elderly patients, whether they live in the community or in long-term care facilities. Management of viral infections in older adults is complicated by factors that include the infrequency or absence of common signs and symptoms of infection and adverse drug reactions. In this article, Drs Bader and McKinsey discuss the clinical features and treatment of herpes zoster and the respiratory diseases caused by influenza and respiratory syncytial virus (RSV).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16329530     DOI: 10.3810/pgm.2005.11.1687

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

1.  Bioconjugated nanoparticle detection of respiratory syncytial virus infection.

Authors:  Ralph A Tripp; Rene Alvarez; Blake Anderson; Les Jones; Craig Weeks; Wei Chen
Journal:  Int J Nanomedicine       Date:  2007

Review 2.  Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults.

Authors:  Ben M Thomas; Paul Farquhar-Smith
Journal:  Ther Clin Risk Manag       Date:  2013-11-25       Impact factor: 2.423

Review 3.  COVID-19 and the elderly: insights into pathogenesis and clinical decision-making.

Authors:  Fabio Perrotta; Graziamaria Corbi; Grazia Mazzeo; Matilde Boccia; Luigi Aronne; Vito D'Agnano; Klara Komici; Gennaro Mazzarella; Roberto Parrella; Andrea Bianco
Journal:  Aging Clin Exp Res       Date:  2020-06-16       Impact factor: 3.636

Review 4.  Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.

Authors:  Benjamin Beal; Tobias Moeller-Bertram; Jan M Schilling; Mark S Wallace
Journal:  Clin Interv Aging       Date:  2012-07-12       Impact factor: 4.458

Review 5.  Treatment of postherpetic neuralgia: focus on pregabalin.

Authors:  Kimberly A Cappuzzo
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.